Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seungah | - |
dc.contributor.author | Lee, Dong Yun | - |
dc.date.accessioned | 2021-07-30T05:25:56Z | - |
dc.date.available | 2021-07-30T05:25:56Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 2287-1012 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4805 | - |
dc.description.abstract | The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic beta-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC PEDIATRIC ENDOCRINOLOGY | - |
dc.title | Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Dong Yun | - |
dc.identifier.doi | 10.6065/apem.2017.22.1.15 | - |
dc.identifier.bibliographicCitation | ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, v.22, no.1, pp.15 - 26 | - |
dc.relation.isPartOf | ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM | - |
dc.citation.title | ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM | - |
dc.citation.volume | 22 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 15 | - |
dc.citation.endPage | 26 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002213208 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalResearchArea | Pediatrics | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Pediatrics | - |
dc.subject.keywordAuthor | Type 2 diabetes | - |
dc.subject.keywordAuthor | Glucagon-like peptide-1 | - |
dc.subject.keywordAuthor | Glucagon-like peptide-1 receptor | - |
dc.subject.keywordAuthor | GLP-1R agonist | - |
dc.subject.keywordAuthor | GLP-1R agonist clinical trials | - |
dc.identifier.url | https://e-apem.org/journal/view.php?doi=10.6065/apem.2017.22.1.15 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.